3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Breast Neoplasms
6
Colorectal Neoplasms
5
Neoplasms
4
Malnutrition
3
Lung Neoplasms
3
Diarrhea
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Mucositis
2
Inflammation
2
Enteritis
2
Chalazion
2
Carcinoma, Hepatocellular
2
Thyroid Neoplasms
1
Squamous Intraepithelial Lesions
1
Smoldering Multiple Myeloma
1
Radiation Injuries
1
Psychological Well-Being
1
Psoriasis Vulgaris
1
Polycystic Ovary Syndrome
1
Periampullary Carcinoma Nos
1
Pelvic Neoplasms
1
Pelvic Inflammatory Disease
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neoplasms, Second Primary
1
Muscle Invasive Bladder Cancer (MIBC)
1
Multiple Myeloma
1
Motor Activity
1
Monoclonal Gammopathy of Undetermined Significance
1
Interventions
Oxaliplatin
290
Capecitabine
206
Fluorouracil
181
Cisplatin
168
Docetaxel
138
S 1 (combination)
132
Paclitaxel
121
Leucovorin
116
Irinotecan
106
pembrolizumab
103
Trastuzumab
72
apatinib
56
Nivolumab
56
sintilimab
45
Drug Therapy
43
Surgical Procedures, Operative
37
Radiotherapy
37
Bevacizumab
37
Ramucirumab
34
titanium silicide
31
Hyperthermic Intraperitoneal Chemotherapy
30
Epirubicin
30
Carboplatin
30
tislelizumab
28
Cyclophosphamide
27
XELOX
24
Tegafur
23
Folfox protocol
22
Albumin-Bound Paclitaxel
22
camrelizumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Stomach Neoplasms
×
Probiotics
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled
NCT06250075
2024-05-13
PRONIC-G
Universidade Federal do Amazonas
Phase NA
Completed
88 enrolled